抗核抗体和特异性自身抗体检测的临床应用

[1] The precipitating antibody to an acitic nuclear protein antigen, the Jo-1, in connective tissue disease.A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Yoshida S,Akizuki M,Mimori T,et al. Arthritis and Rheumatism . 1983

[2] The clinical significance of autoantibody profiles in patients with SLE. Thompson D,Juby A,Davis P. Lupus . 1993

[3] Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue disease. Combe B,Rucheton M,Graafland H,et al. Clinical and Experimental Immunology . 1989

[4] Significance of the anti-Ro(SS-A) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease. Provost TT,Watson R,Simmons-O′Brien E. Journal of the American Academy of Dermatology . 1996

[5] Antinuclear antibody determinations in Ro ( SS-A)-positive, antinuclear antibody-negative lupus and Sjogron′s syndrome patients. Dore N,Synkowski D,Provost TT. Journal of the American Academy of Dermatology . 1983

[6] Scl-70 antibodies: a specific marker of systemic sclerosis. Jarzabek-Chorzelska M,Blaszczyk M,Jablonska S,et al. Br J Dermatol . 1986

[7] Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Kavanaugh A,Tomar R,Reveille J,et al. Archives of Pathology and Laboratory Medicine . 2000

[8] Immunoe responses to SS-A 52-kDa and 60-kDa proteins and to SS-B 50-kDa protein in mothers of infants with neonatal lupus erythematosus. Yukiko N. Br J Dermatol . 2000

[9] Serologic markers of disease activity in SLE. Sprionk PE,Limburg PC,Kallenberg GM. Lupus . 1995

[10] Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians. Suarez-Almazor ME,Gonzalez-Lopez L,Gamez-Nava JI,et al. The Journal of Rheumatology . 1998

[1] The precipitating antibody to an acitic nuclear protein antigen, the Jo-1, in connective tissue disease.A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Yoshida S,Akizuki M,Mimori T,et al. Arthritis and Rheumatism . 1983

[2] The clinical significance of autoantibody profiles in patients with SLE. Thompson D,Juby A,Davis P. Lupus . 1993

[3] Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue disease. Combe B,Rucheton M,Graafland H,et al. Clinical and Experimental Immunology . 1989

[4] Significance of the anti-Ro(SS-A) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease. Provost TT,Watson R,Simmons-O′Brien E. Journal of the American Academy of Dermatology . 1996

[5] Antinuclear antibody determinations in Ro ( SS-A)-positive, antinuclear antibody-negative lupus and Sjogron′s syndrome patients. Dore N,Synkowski D,Provost TT. Journal of the American Academy of Dermatology . 1983

[6] Scl-70 antibodies: a specific marker of systemic sclerosis. Jarzabek-Chorzelska M,Blaszczyk M,Jablonska S,et al. Br J Dermatol . 1986

[7] Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Kavanaugh A,Tomar R,Reveille J,et al. Archives of Pathology and Laboratory Medicine . 2000

[8] Immunoe responses to SS-A 52-kDa and 60-kDa proteins and to SS-B 50-kDa protein in mothers of infants with neonatal lupus erythematosus. Yukiko N. Br J Dermatol . 2000

[9] Serologic markers of disease activity in SLE. Sprionk PE,Limburg PC,Kallenberg GM. Lupus . 1995

[10] Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians. Suarez-Almazor ME,Gonzalez-Lopez L,Gamez-Nava JI,et al. The Journal of Rheumatology . 1998